Sai Life Sciences Q1FY26 Revenue Rises 77 Per Cent YoY
ECONOMY & POLICY

Sai Life Sciences Q1FY26 Revenue Rises 77 Per Cent YoY

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO), reported strong financial results for the first quarter of fiscal year 2026, led by significant growth in its CDMO segment.
Revenue from operations in Q1FY26 stood at Rs 4.96 billion, a 77 per cent increase over the Rs 2.80 billion recorded in Q1FY25. The company reported EBITDA of Rs 1.25 billion, a 305 per cent year-on-year jump, while EBITDA margin expanded by 14 percentage points to 25 per cent. Profit after tax stood at Rs 600 million for the quarter.
Sai Life Sciences invested Rs 1.34 billion in capital expenditure during the quarter, reflecting its commitment to infrastructure expansion and scientific innovation.
Key business milestones included the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), adding 91 KL of capacity and bringing the total manufacturing capacity to approximately 700 KL. The company also inaugurated a new Peptide Research Centre at its Hyderabad R&D campus, as well as a 10,300 sq. ft. biology facility with multiple laboratories to bolster its integrated discovery platform.
Construction is underway on a new Medicinal Chemistry block with capacity for 200 fume hoods and a new Process R&D Block at Unit 2, Hyderabad. This expansion is expected to nearly double the company’s PRD capacity and enhance its capabilities in early-phase peptide development and clinical formulations. Additionally, Sai Life is preparing to build an extra 200 KL production capacity at Bidar, set for completion by Q3FY27.
To support this growth, the company onboarded 253 new scientists and technical staff in Q1FY26.
Managing Director and CEO Mr Krishna Kanumuri stated, “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. These investments reflect our proactive approach in supporting complex and emerging drug modalities.”
CFO Mr Siva Chittor added, “Our robust Q1FY26 performance was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues. Margin expansion was driven by scale efficiencies, productivity gains, and operating leverage across sites.”
Looking ahead, the company remains focused on scaling execution, deepening client partnerships, and investing in R&D capabilities to sustain long-term value creation.

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO), reported strong financial results for the first quarter of fiscal year 2026, led by significant growth in its CDMO segment.Revenue from operations in Q1FY26 stood at Rs 4.96 billion, a 77 per cent increase over the Rs 2.80 billion recorded in Q1FY25. The company reported EBITDA of Rs 1.25 billion, a 305 per cent year-on-year jump, while EBITDA margin expanded by 14 percentage points to 25 per cent. Profit after tax stood at Rs 600 million for the quarter.Sai Life Sciences invested Rs 1.34 billion in capital expenditure during the quarter, reflecting its commitment to infrastructure expansion and scientific innovation.Key business milestones included the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), adding 91 KL of capacity and bringing the total manufacturing capacity to approximately 700 KL. The company also inaugurated a new Peptide Research Centre at its Hyderabad R&D campus, as well as a 10,300 sq. ft. biology facility with multiple laboratories to bolster its integrated discovery platform.Construction is underway on a new Medicinal Chemistry block with capacity for 200 fume hoods and a new Process R&D Block at Unit 2, Hyderabad. This expansion is expected to nearly double the company’s PRD capacity and enhance its capabilities in early-phase peptide development and clinical formulations. Additionally, Sai Life is preparing to build an extra 200 KL production capacity at Bidar, set for completion by Q3FY27.To support this growth, the company onboarded 253 new scientists and technical staff in Q1FY26.Managing Director and CEO Mr Krishna Kanumuri stated, “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. These investments reflect our proactive approach in supporting complex and emerging drug modalities.”CFO Mr Siva Chittor added, “Our robust Q1FY26 performance was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues. Margin expansion was driven by scale efficiencies, productivity gains, and operating leverage across sites.”Looking ahead, the company remains focused on scaling execution, deepening client partnerships, and investing in R&D capabilities to sustain long-term value creation. 

Next Story
Infrastructure Transport

India Becomes First to Produce Bio-Bitumen for Roads

India has become the first country in the world to commercially produce bio-bitumen for use in road construction, according to Road, Transport and Highways Minister Nitin Gadkari. Bitumen, a black and viscous hydrocarbon derived from crude oil, is a key binding material in road building, and the bio-based alternative is expected to significantly improve the sector’s environmental footprint.Addressing the CSIR Technology Transfer Ceremony in New Delhi, Mr Gadkari congratulated Council of Scientific and Industrial Research on achieving the milestone, noting that the initiative would help curb ..

Next Story
Infrastructure Urban

HILT Policy Seen Boosting Telangana Revenue Sharply

The Hyderabad Industrial Land Transformation (HILT) Policy is expected to generate around Rs 1.08 billion in revenue for the Telangana state exchequer, according to Deputy Chief Minister Bhatti Vikramarka Mallu. Speaking in the Telangana Legislative Assembly, he said the policy would be implemented within a six-month timeframe in a transparent manner, with uniform rules applicable to all stakeholders. Mr Vikramarka noted that without the HILT Policy, the state would have earned only about Rs 1.2 million per acre. Under the new framework, however, revenue is projected to rise sharply to Rs 70 ..

Next Story
Infrastructure Urban

India Post, MoRD Tie Up to Boost Rural Inclusion

The Department of Posts and the Ministry of Rural Development have signed a Memorandum of Understanding to accelerate rural transformation and expand financial, digital and logistics services for Self-Help Groups (SHGs) and rural households across India. The agreement was signed in the presence of Union Minister of Communications and Development of North Eastern Region Jyotiraditya M. Scindia and Union Minister of Rural Development and Agriculture and Farmers’ Welfare Shivraj Singh Chouhan. The collaboration aligns with the government’s “Dak Sewa, Jan Sewa” vision and seeks to repositi..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Open In App